Dongwha Pharm.Co.,Ltd (000020.KS) Stock
Dongwha Pharm.Co.,Ltd

Company profile
Dongwha Pharm.Co.,Ltd reported revenue of 496.39 billion KRW for fiscal year 2025, up 6.8% from fiscal year 2024, and net income of 8.69 billion KRW. That is a net profit margin of 1.7% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 130.61 billion KRW, up 3.9% from a year before. Its largest business segment, Pharmaceutical Industry, brought in 78% of segment revenue in fiscal year 2024; South Korea was the largest region with 78%. In Q1 2026 it reported net income of 10.02 billion KRW, against net income of 34.33 million KRW a year earlier. Our analysis of its filings shows revenue growing from 361.11 billion KRW in fiscal year 2023 to 496.39 billion KRW in fiscal year 2025, 17.2% a year on average. Dongwha Pharm.Co.,Ltd reports about 795 full-time employees.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Dongwha Pharm.Co.,Ltd
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company also exports its products. Dongwha Pharm.Co.,Ltd was founded in 1897 and is headquartered in Seoul, South Korea.
Largest shareholders
- In-Ho Yoon21.66 %21.66%
- Gasong Foundation6.39%
- Gil-Joon Yoon1.837 %1.84%
- Do-Joon Yoon1 %1.00%
- Dong Wha Development Co., Ltd.0.77%
Share of the company, as of September 25, 2026
Leadership
- Doh Joon Yoon M.D., Ph.D. — Chairman of the Board & Co-CEO, 73
- Chang-Soo Cho — Co-CEO & President, 76
In the news
How much revenue does Dongwha Pharm.Co.,Ltd make?
Dongwha Pharm.Co.,Ltd reported 496.39 billion KRW in revenue for fiscal year 2025, up 6.8% from 464.87 billion KRW in fiscal year 2024. In Q1 2026 revenue was 130.61 billion KRW.
What is Dongwha Pharm.Co.,Ltd's largest business segment?
Pharmaceutical Industry, with 363.80 billion KRW or 78% of segment revenue in fiscal year 2024. Next: Medicines Distribution Chain (16%) and Medical Equipment Manufacturing (5%).
Where does Dongwha Pharm.Co.,Ltd make most of its revenue?
South Korea: 78% of revenue by region in fiscal year 2024, followed by Overseas (22%).
What companies are similar to Dongwha Pharm.Co.,Ltd?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Yungjin Pharm. Co., Ltd. (003520.KS), Ilsung Is Co., Ltd. (003120.KS), Hana Pharm Co., Ltd. (293480.KS), Jeil Pharmaceutical Co.,Ltd (271980.KS).
How has Dongwha Pharm.Co.,Ltd's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 293.02 billion KRW; FY2022, 340.43 billion KRW; FY2023, 361.11 billion KRW; FY2024, 464.87 billion KRW; FY2025, 496.39 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Dongwha Pharm.Co.,Ltd (000020.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/000020.KS